

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **December 2, 2019**

NextCure, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction
of incorporation)

001-38905

(Commission
File Number)

47-5231247

(IRS Employer
Identification No.)

**9000 Virginia Manor Road, Suite 200
Beltsville, Maryland**

(Address of principal executive offices)

20705

(Zip Code)

(240) 399-4900

Registrant's telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	NXTC	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

NextCure, Inc., a Delaware corporation (the “**Company**”), announced today that the underwriters for its recent underwritten public offering of common stock (the “**Offering**”) exercised in full their option to purchase an additional 611,578 shares of common stock of the Company at the public offering price of \$36.75 per share (the “**Option Exercise**”). The original closing of the Offering was on November 19, 2019, and the Option Exercise closed on December 2, 2019. The gross proceeds to the Company from the Option Exercise, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately \$22.5 million, bringing the total gross proceeds to the Company from the Offering to approximately \$172.3 million.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 2, 2019

NEXTCURE, INC.

/s/ Steven P. Cobourn
Steven P. Cobourn
Chief Financial Officer
